Natera, Inc. $NTRA Shares Sold by Nisa Investment Advisors LLC

Nisa Investment Advisors LLC cut its holdings in Natera, Inc. (NASDAQ:NTRA) by 13.1% during the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 21,525 shares of the medical research company’s stock after selling 3,239 shares during the period. Nisa Investment Advisors LLC’s holdings in Natera were worth $3,465,000 as of its most recent SEC filing.

Several other hedge funds have also recently added to or reduced their stakes in the business. Lecap Asset Management Ltd. acquired a new position in Natera during the third quarter worth about $570,000. SG Americas Securities LLC raised its position in shares of Natera by 1,645.4% during the 3rd quarter. SG Americas Securities LLC now owns 77,704 shares of the medical research company’s stock worth $12,508,000 after purchasing an additional 73,252 shares during the last quarter. HB Wealth Management LLC acquired a new position in shares of Natera during the 3rd quarter worth approximately $338,000. KLP Kapitalforvaltning AS lifted its position in shares of Natera by 7.9% in the third quarter. KLP Kapitalforvaltning AS now owns 47,900 shares of the medical research company’s stock valued at $7,710,000 after acquiring an additional 3,500 shares in the last quarter. Finally, Cerity Partners LLC increased its position in Natera by 12.2% during the 3rd quarter. Cerity Partners LLC now owns 109,463 shares of the medical research company’s stock worth $17,620,000 after purchasing an additional 11,890 shares in the last quarter. 99.90% of the stock is currently owned by hedge funds and other institutional investors.

Natera Stock Up 0.5%

Shares of NASDAQ NTRA opened at $235.45 on Tuesday. The stock has a market capitalization of $32.57 billion, a PE ratio of -102.82 and a beta of 1.62. The firm has a fifty day moving average of $227.79 and a 200-day moving average of $186.82. Natera, Inc. has a 52-week low of $125.38 and a 52-week high of $256.36.

Natera (NASDAQ:NTRA) last issued its earnings results on Friday, November 7th. The medical research company reported ($0.64) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.25). Natera had a negative net margin of 14.61% and a negative return on equity of 25.07%. The firm had revenue of $592.18 million during the quarter, compared to analyst estimates of $514.55 million. During the same quarter in the previous year, the business posted ($0.26) EPS. Natera’s revenue was up 34.7% compared to the same quarter last year. Equities research analysts expect that Natera, Inc. will post -1.49 EPS for the current fiscal year.

Analyst Ratings Changes

Several research firms have issued reports on NTRA. Piper Sandler raised their price target on shares of Natera from $220.00 to $230.00 and gave the stock an “overweight” rating in a research note on Tuesday, November 11th. Zacks Research upgraded shares of Natera from a “strong sell” rating to a “hold” rating in a research report on Thursday, January 1st. Evercore ISI lifted their target price on shares of Natera from $190.00 to $250.00 and gave the stock an “outperform” rating in a research note on Friday, November 7th. Morgan Stanley increased their price target on Natera from $220.00 to $265.00 and gave the stock an “overweight” rating in a research note on Monday, December 1st. Finally, Cowen reaffirmed a “buy” rating on shares of Natera in a research report on Wednesday, January 7th. One analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $241.18.

Insiders Place Their Bets

In related news, CEO Steven Leonard Chapman sold 160,703 shares of the firm’s stock in a transaction that occurred on Monday, November 3rd. The shares were sold at an average price of $199.96, for a total value of $32,134,171.88. Following the transaction, the chief executive officer owned 144,816 shares in the company, valued at approximately $28,957,407.36. This trade represents a 52.60% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, insider Solomon Moshkevich sold 4,692 shares of Natera stock in a transaction that occurred on Friday, December 12th. The shares were sold at an average price of $230.76, for a total transaction of $1,082,725.92. Following the transaction, the insider directly owned 113,065 shares in the company, valued at approximately $26,090,879.40. This trade represents a 3.98% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last ninety days, insiders sold 343,280 shares of company stock worth $73,566,011. 5.63% of the stock is owned by insiders.

About Natera

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.